We bring you the latest news from the healthcare about the health care in the United Kingdom.

woensdag 28 februari 2018

Nature Reviews Drug Discovery contents March 2018 Volume 17 Number 3 pp 151-223

If you are unable to see the message below, click here to view.
Nature Reviews Drug Discovery

Analyze Large and Small Molecule Inhibitors in a Single Homogeneous Assay

Want to analyze downstream cell signaling events impacted by both large and small molecule inhibitors in a single assay? Learn about a no-wash platform for screening antibodies and small molecule inhibitors, in this example used to characterize chemokine receptor inhibitors. 

Download Application Note
March 2018 Volume 17 Number 3 Advertisement
Nature Reviews Drug Discovery cover
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38
In this issue
News and Analysis
Research Highlights
Also this month
 Featured article:
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter & Greg A. Lazar

Do you have a career question?
The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today! 

Recommend to library
Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics 
May 22, 2018, NYC

Nathanael S. Gray of Harvard Medical School joins other top experts for a one-day symposium exploring emerging approaches to advance the discovery of novel non-classical kinase inhibitors.
Abstract deadline March 23rd.

Find more information and register here. 

BioPharma DealmakersCompany Profiles and Partnering Opportunities

Nature Outlook: Fatty liver disease

The worldwide rise in obesity and diabetes has led to a spike in non-alcoholic fatty liver disease, which often progresses to the more severe non-alcoholic steatohepatitis. This Outlook discusses new diagnostic techniques and therapies. 

Access the Outlook free online >> 

Produced with support from: 
Gilead Sciences 
A new open access, multi- and interdisciplinary journal dedicated to publishing the highest quality papers on aging and age-related diseases, the journal is now open for submissions.
Explore the benefits of submitting your next research.
Comment: Addressing challenges in the diagnosis and treatment of rare genetic diseases
Kym M. Boycott & Diego Ardigo

p151 | doi:10.1038/nrd.2017.246
The past 5 years have seen an unprecedented rate of discovery of genes that cause rare diseases and with it a commensurate increase in the number of diagnosable but nevertheless untreatable disorders. Here, we discuss the increasing opportunity for diagnosis and therapy of rare diseases and how to tackle the associated challenges.
Abstract | Full Text | PDF

Oncologists tap the microbiome in bid to improve immunotherapy outcomes
Asher Mullard

p153 | doi:10.1038/nrd.2018.19
A pioneering Merck & Co.-funded study is set to explore the ability of the microbiome to boost immuno-oncology therapy outcomes, and other companies are quickly gearing up to enter this clinical space.
Alnylam prepares to land first RNAi drug approval
Chris Morrison

p156 | doi:10.1038/nrd.2018.20
With Alnylam's rare disease drug candidate patisiran nearing the regulatory finish line, the RNA interference community is now turning its attention to next-generation delivery technology to solidify the future of the emerging modality.
Fiona Marshall
p158 | doi:10.1038/nrd.2018.25
Fiona Marshall — co-founder of Heptares, former chief scientific officer of Sosei and soon to be lead of Merck & Co.'s new research facility in London — looks back on 30 years of GPCRs, and looks forward to the emerging therapeutic opportunities these targets still offer.
The market for chimeric antigen receptor T cell therapies
Amy Yip & Rachel M. Webster

p161 | doi:10.1038/nrd.2017.266
This article discusses the market for chimeric antigen receptor (CAR) T cell therapies, focusing on haematological malignancies.

Cancer: Fibroblast subtype provides niche for cancer stem cells
p163 | doi:10.1038/nrd.2018.23

Cancer: New path to improving immunotherapy
p164 | doi:10.1038/nrd.2018.22

Immunotherapy: Direct shot
p165 | doi:10.1038/nrd.2018.29

Cancer: Reset your circadian clock
p166 | doi:10.1038/nrd.2018.24



Cardiovascular disease: Inhalation therapy for heart failure | Antibacterials: Synthetic peptides eradicate resistant infections | Alzheimer disease: Identification of blood-based biomarkers | Cancer: Targeting the ubiquitin pathway

Drug Discovery
JOBS of the week
Postdoctoral Fellow Position Available
National Cancer Institute (NCI)
Research Fellow X 2 (Level A or Level B)
Monash University
Postdoctoral Fellow Position Available
National Institutes of Health (NIH), Department of Health and Human Services (HHS)
Associate Principle Scientist, Inform & Analytics
Merck Sharpe & Dohme Corp.
Postdoctoral Associate
University of Minnesota - College of Pharmacy
More Science jobs from
Drug Discovery
G36 Effective Project Management for Clinical Trials
Maidenhead, UK
More science events from
Nature Collection: 2017 Nobel Prize in Physiology or Medicine

The 2017 Nobel Prize in Physiology or Medicine was awarded to Jeffrey C. Hall, Michael Rosbash and Michael W. Young for their pioneering work in Drosophila that elucidated the molecular mechanisms controlling circadian rhythm. 

Access this collection free online>>

Produced with support from: 
Vanda Pharmaceuticals
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Paul Morgan, Dean G. Brown, Simon Lennard, Mark J. Anderton, J. Carl Barrett, Ulf Eriksson, Mark Fidock, Bengt Hamrén, Anthony Johnson, Ruth E. March, James Matcham, Jerome Mettetal, David J. Nicholls, Stefan Platz, Steve Rees, Michael A. Snowden & Menelas N. Pangalos

p167 | doi:10.1038/nrd.2017.244
In 2011, AstraZeneca set out to improve its research and development (R&D) productivity by focusing decision-making using a framework with five technical determinants: the right target, right tissue, right safety, right patient and right commercial potential. Here, Pangalos and colleagues describe the progress made using this '5R framework', with metrics indicating improved success rates, and discuss where the approach has failed and the lessons learned.
Abstract | Full Text | PDF | Supplementary information

nature.com webcasts

Springer Nature presents a custom webcast on: Sequencing Structural Variants for Disease Gene Discovery and Population Genetics

Date: Thursday, March 8, 2018 

Register for FREE 

Sponsored by: PacBio 
Drug development in the era of precision medicine
Sarah A. Dugger, Adam Platt & David B. Goldstein

p183 | doi:10.1038/nrd.2017.226
The contribution of genomics to drug discovery and development so far has not yet lived up to the initial high expectations. Goldstein and colleagues discuss the reasons for the limited progress and review how recent advances — particularly in oncology and rare genetic diseases — may enable precision medicine strategies to harness the therapeutic potential of genomic knowledge.
Abstract | Full Text | PDF

Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter & Greg A. Lazar

p197 | doi:10.1038/nrd.2017.227
Antibody therapeutics are now established as a major drug class. Here, Carter and Lazar comprehensively discuss current and emerging platforms and technologies for antibody therapeutics, with an emphasis on approaches that could extend their therapeutic applications, including antibody-drug conjugates, bispecific antibodies and antibody engineering to enable more effective delivery.
Abstract | Full Text | PDF

npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions.
Explore the benefits of submitting your next manuscript to the journal.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature